Ott_a_223643 11541..11547

1Department of Thoracic Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou 350014, People’s Republic of China; 2Department of Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou 350014, People’s Republic of China; 3Department of Molecular Pathology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou 350014, People’s Republic of China; 4Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou 350014, People’s Republic of China; 5Department of Pathology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350014, People’s Republic of China; 6Department of Oncology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471003, People’s Republic of China; 7Department of Cardiac Surgery, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471003, People’s Republic of China Introduction: Programmed death-ligand 1 (PD-L1) expression as measured by immuno-